Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Mucocutaneous Lymph Node Syndrome | 8 | 2021 | 1645 | 1.50 | Why? |
| Coronary Aneurysm | 3 | 2019 | 132 | 1.31 | Why? |
| Immunoglobulins, Intravenous | 5 | 2021 | 2705 | 0.86 | Why? |
| Systemic Inflammatory Response Syndrome | 9 | 2021 | 6653 | 0.78 | Why? |
| Immunomodulation | 3 | 2021 | 1472 | 0.59 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 2 | 2021 | 1165 | 0.50 | Why? |
| Ventricular Dysfunction, Left | 1 | 2021 | 993 | 0.49 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.39 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.39 | Why? |
| Echocardiography | 3 | 2019 | 3661 | 0.39 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.32 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.25 | Why? |
| Child, Preschool | 10 | 2021 | 36283 | 0.20 | Why? |
| Enteritis | 1 | 2021 | 147 | 0.20 | Why? |
| Atrioventricular Block | 1 | 2020 | 105 | 0.19 | Why? |
| Infant | 7 | 2021 | 30274 | 0.19 | Why? |
| Macrophage Activation Syndrome | 1 | 2020 | 342 | 0.16 | Why? |
| Child | 11 | 2021 | 70012 | 0.15 | Why? |
| Paris | 1 | 2020 | 1287 | 0.15 | Why? |
| Boston | 1 | 2019 | 929 | 0.15 | Why? |
| Drug Therapy, Combination | 2 | 2021 | 7268 | 0.15 | Why? |
| Asian Americans | 1 | 2019 | 387 | 0.15 | Why? |
| Interleukin-10 | 1 | 2020 | 1409 | 0.13 | Why? |
| Shock | 1 | 2021 | 1868 | 0.13 | Why? |
| Natriuretic Peptide, Brain | 1 | 2020 | 1215 | 0.13 | Why? |
| Predictive Value of Tests | 2 | 2019 | 9537 | 0.12 | Why? |
| Diagnosis, Differential | 4 | 2021 | 7220 | 0.12 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.12 | Why? |
| North America | 1 | 2017 | 1400 | 0.12 | Why? |
| California | 1 | 2019 | 2047 | 0.12 | Why? |
| Combined Modality Therapy | 1 | 2021 | 3395 | 0.12 | Why? |
| Social Class | 1 | 2019 | 1360 | 0.11 | Why? |
| Adolescent | 8 | 2021 | 86841 | 0.11 | Why? |
| Biomarkers | 4 | 2021 | 23361 | 0.10 | Why? |
| Aspirin | 1 | 2018 | 1043 | 0.10 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.09 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 1454 | 0.09 | Why? |
| Public Health Surveillance | 1 | 2021 | 3129 | 0.09 | Why? |
| Bacterial Infections | 1 | 2021 | 2229 | 0.08 | Why? |
| Prospective Studies | 3 | 2020 | 43301 | 0.08 | Why? |
| Logistic Models | 1 | 2021 | 9089 | 0.08 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.07 | Why? |
| Immunologic Factors | 2 | 2021 | 4206 | 0.07 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Japan | 1 | 2018 | 6653 | 0.07 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.07 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.07 | Why? |
| France | 1 | 2020 | 12074 | 0.07 | Why? |
| Male | 10 | 2021 | 367725 | 0.06 | Why? |
| Inflammation | 3 | 2021 | 13255 | 0.06 | Why? |
| Female | 10 | 2021 | 380317 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2019 | 7972 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Risk Factors | 4 | 2020 | 71621 | 0.06 | Why? |
| Nervous System Diseases | 1 | 2021 | 4092 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2019 | 5883 | 0.06 | Why? |
| Humans | 14 | 2021 | 930598 | 0.05 | Why? |
| Health Status Disparities | 1 | 2019 | 4072 | 0.05 | Why? |
| Fever | 1 | 2018 | 7795 | 0.05 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.05 | Why? |
| United States | 4 | 2021 | 46150 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.05 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.04 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.04 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Delphi Technique | 1 | 2021 | 1257 | 0.04 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.04 | Why? |
| Diagnostic Errors | 1 | 2021 | 865 | 0.03 | Why? |
| Intensive Care Units, Pediatric | 1 | 2021 | 1098 | 0.03 | Why? |
| Patient Acuity | 1 | 2021 | 1755 | 0.03 | Why? |
| Advisory Committees | 1 | 2021 | 1418 | 0.03 | Why? |
| Regression Analysis | 1 | 2021 | 2484 | 0.03 | Why? |
| Critical Care | 3 | 2021 | 14081 | 0.03 | Why? |
| Linear Models | 1 | 2019 | 1914 | 0.03 | Why? |
| Stroke Volume | 1 | 2021 | 2153 | 0.03 | Why? |
| Rheumatology | 1 | 2021 | 1213 | 0.03 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2021 | 1671 | 0.03 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.02 | Why? |
| Residence Characteristics | 1 | 2019 | 1927 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Symptom Assessment | 1 | 2021 | 4967 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2021 | 3023 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.01 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
Son's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(93)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(133)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_